Aneuploidy and genomic instability are common features of human cancers, including breast cancer; however, mechanisms by which such abnormalities develop are not understood. The exquisite dependence of the mammary gland on hormones for growth and development as well as hormonal contributions to breast cancer risk and progression suggest that tumorigenic mechanisms in the breast should be considered in the context of hormonal stimulation. We used transgenic mice that overexpress luteinizing hormone with subsequent ovarian hyperstimulation as a model to identify mechanisms involved in hormone-induced mammary cancer. Tumor pathology in these mice is highly variable, suggesting individual tumors undergo distinct initiating or promoting events. Supporting this notion, hormone-induced tumors display considerable chromosomal instability and aneuploidy, despite the presence of functional p53. The presence of extensive centrosome amplification in tumors and hyperplastic glands prior to tumor formation suggests that alterations in the ovarian hormonal milieu dysregulate the centrosome cycle in mammary epithelial cells, leading to aneuploidy and cancer.
Introduction
Chromosomal abnormalities are a distinguishing feature of cancer cells. The frequency with which aneuploidy is observed in human tumors has led to assertions that such aberrations are a universal and necessary characteristic of malignancy (Duesberg et al., 2005) . Cells with an inappropriate assemblage of chromosomes normally undergo cell-cycle arrest or apoptosis. However, under some circumstances, cells acquire a complement of chromosomes that favors unregulated growth. While the mechanisms driving aneuploidy are not fully understood, they probably result from a variety of genetic and cellular insults, the most conspicuous being infidelities in mitotic spindle formation and chromosome segregation (Pihan and Doxsey, 1999) .
Centrosomal aberrations have been observed in a diverse array of human tumors, including those of the breast (Lingle et al., 1998 (Lingle et al., , 2002 Lingle and Salisbury, 1999; D'Assoro et al., 2002) . It has been hypothesized that supernumerary centrosomes induce multipolar spindles, leading to mis-segregation of chromosomes and creation of aneuploid daughter cells. Supporting this hypothesis, centrosome amplification correlates with aneuploidy and chromosomal instability in breast cancer (Lingle et al., 2002) . However, it is unclear whether centrosome amplification is a cause or byproduct of tumorigenesis. Supporting the former are observations that centrosome amplification is an early event in tumorigenesis (Goepfert et al., 2002; Lingle et al., 2002; Pihan et al., 2003) and recent studies showing that human diploid mammary epithelial cells (MECs) with supernumerary centrosomes can generate aneuploid daughter cells (McDermott et al., 2006) . p53 is mutated in 50% of human cancers and has been extensively correlated with aneuploidy, genomic instability and centrosome amplification. p53-null MECs transplanted into the mammary gland fat pads of wildtype mice develop spontaneous tumors with high penetrance . An increase in tumor formation was observed in the presence of hormonal stimulation with pituitary isografts, resulting in adenocarcinomas with varying composition of aneuploid cells (Jerry et al., 2000) . These data suggest that hormonal stimulation contributes to the acquisition of aneuploidy in a p53-deficient environment. While p53 can regulate murine mammary tumor formation, its role in human breast cancer is less clear. Only B20% of breast cancers have mutations in p53 (Pharoah et al., 1999) and, although up to 80% of human breast tumors display chromosomal and centrosomal abnormalities, these characteristics do not correlate with the presence of p53 mutations (Lingle et al., 2002) .
Hormones have been implicated in the initiation and progression of breast cancer. Early menarche and late menopause both impart increased risk (Brinton et al., 1988; Kvale and Heuch 1988; Hsieh et al., 1990) , and removal of ovarian hormones by pre-menopausal bilateral oophorectomy conveys a protective effect against breast cancer (Irwin et al., 1988) . The role of hormones has been reinforced by the remarkable efficacy of antihormone therapies for treatment and prevention of breast cancer (Early Breast Cancer Trialists' Collaborative Group, 1998; Fisher et al., 1998; Bonneterre et al., 2001; Baum et al., 2002; Buzdar et al., 2006) . However, the specific mechanisms by which hormones contribute to breast cancer are largely unknown.
While hormone exposure and genomic instability have both been linked to breast tumorigenesis, little is known regarding the relationship between them. We utilized a transgenic mouse model of hormone-induced mammary tumorigenesis, the LH (luteinizing hormone)-overexpressing mouse (Milliken et al., 2002) , to investigate this relationship. In response to elevated LH derived from the pituitary, these mice have increased serum levels of estradiol, progesterone and prolactin. They develop diffuse mammary epithelial hyperplasia by 5 weeks of age and aged mice (>20 weeks) develop mammary intraepithelial neoplasias (MIN) that arise from the lobuloalveolar unit. Approximately 50% of mice develop palpable tumors by 41 weeks of age and tumors are metastatic to the lung (Milliken et al., 2002) . Herein we report that these hormone-induced mammary tumors are morphologically heterogeneous and exhibit substantial levels of aneuploidy with accumulation of sub-chromosomal genomic aberrations. Although tumor formation does not depend on loss of functional p53, it is preceded by centrosome amplification, suggesting that increased exposure to reproductive hormones may induce genomic instability in the mammary gland through accumulation of supernumerary centrosomes.
Results
Mammary tumors of LH-overexpressing mice are histologically diverse Using criteria set forth by the Annapolis Pathology Panel (Cardiff et al., 2000) , we found that mammary tumors from LH-overexpressing mice had regions of the following histopathologies: squamous (52%), cribriform (32%), solid (26%), papillary (16%), glandular (16%) or acinar (5%) (Figure 1 and Supplementary Table 1) . Additionally, 42% (8/19) of tumors analysed displayed intratumoral heterogeneity (2-3 distinct histopathologies;
Supplementary Table 1 ). These data suggest that while mammary tumors of LH-overexpressing mice are hormonally induced, they may not progress through a uniform mechanism. We hypothesized that chronic hormonal stimulation induces genomic instability in the mammary glands of these mice, leading to diverse tumor initiating or promoting events.
Mammary tumors of LH-overexpressing mice are aneuploid One potential manifestation of genomic instability is the presence of aneuploidy. While normal wild-type MECs rarely demonstrate alterations in chromosome number (Goepfert et al., 2002) , chromosome quantification revealed that the majority of cells in mammary tumors of LH-overexpressing mice exhibit aberrant chromosome numbers (Figure 2 ). Across all tumors evaluated, 25.9-27.0% of cells were diploid and 6.7-7.5% were near diploid, while all three tumors contained 67% aneuploid cells. The percentage of aneuploid cells was remarkably consistent among tumors; however, the intratumoral chromosome number per cell was highly variable (42-65 chromosomes per hyperploid cell). Thus, extensive chromosomal instability was a hallmark of these tumors.
To determine if specific chromosomes or regions of chromosomes were consistently gained or lost within tumors, we performed array-based comparative genomic hybridization (CGH) on nine additional tumors. Consistent with the high intratumoral variability in chromosome number, most tumors failed to display consistent large regions of gains or losses. One tumor had a net loss of chromosome 4 and another tumor displayed a gain of chromosome 11 (data not shown). Small aberrations were observed in significant subsets of (Figure 3 and Supplementary Table 2 ), suggesting that changes in the copy number of these genes may convey a selective growth advantage.
Mammary tumors of LH-overexpressing mice develop aneuploidy independent of mutations in p53
To determine if p53 mutations may contribute to hormone-induced aneuploidy and tumorigenesis, we sequenced virtually the entire coding region of tumorderived p53 cDNA. No evidence of mutations was found when tumor cDNA (n ¼ 8) was compared to that of wild-type littermates (n ¼ 4) (data not shown). These data indicate that wild-type p53 mRNA is expressed in mammary tumors of LH-overexpressing mice.
p53 can be inactivated by overexpression of mdm2, a ubiquitin ligase, that regulates p53 protein stability (Mayo and Donner, 2002) . Quantitative real-time RT-PCR and western blot analysis showed that mdm2 expression is unchanged in hyperplastic glands and tumors compared to wild-type mammary glands (Supplementary Figure 1) . MdmX mRNA levels were increased 1.5-fold in hyperplastic tissue. However, this increase was not maintained in tumors, which displayed a 43% reduction in mdmX mRNA compared to wildtype glands.
p53 activity and apoptosis are induced by ionizing radiation in mammary glands of wild-type and LHoverexpressing mice To assess the functional capacity of p53 in the mammary glands of LH-overexpressing mice, we used ionizing radiation (IR) to activate the p53 signaling pathway (Fei and El Deiry 2003) . Western blot analysis revealed significant serine 18 phosphorylation of p53 in wild-type and transgenic mammary glands, as well as in tumors within 2 h of IR exposure (data not shown), indicating that the portion of the p53 signaling pathway initiated by double-strand DNA breaks (Ewan et al., 2002) is intact in hyperplastic tissue and established tumors. We also measured induction of two p53 target genes: p21 and Bax. Baseline p21 mRNA levels were not significantly different between the mammary glands from transgenic and wild-type mice, and strong induction of p21 was observed in both wild-type (12.5-fold) and transgenic (7.1-fold) mammary glands 6 h after exposure to IR (Figure 4a ). p21 mRNA levels trended towards being less robustly induced in IR-treated LHoverexpressing mice compared to wild-type animals; however, it did not reach statistical significance. Bax induction was also observed in irradiated mice, independent of genotype (data not shown). Together, these data strongly suggest that p53 signaling is functionally active in response to double-strand DNA breaks.
If p53 function is attenuated in the mammary glands of LH-overexpressing mice, radiation-induced apoptosis should be diminished compared to wild-type mammary glands (Backlund et al., 2001) . Adult wild-type and transgenic mice were exposed to IR and apoptosis was measured. No statistically significant difference in IR-induced apoptosis was detected between the mammary glands of wild-type-and LH-overexpressing mice (Figure 4b ). Although the lymph nodes housed within the inguinal mammary glands demonstrated consistently high levels of IR-induced apoptosis (data not shown), extensive variability was observed in MECs. Wild-type mice displayed two distinct populations of apoptotic response to IR; this variation did not correlate with stage of the estrous cycle or serum progesterone levels (data not shown). In contrast, apoptotic rates in the LHoverexpressing mice showed a more uniform distribution. These data indicate that p53 can be activated in mammary glands of LH-overexpressing mice in response to genotoxic stress and that the altered hormonal milieu does not impart protection from radiationinduced apoptosis.
Expression of a mutant form of p53 does not alter the latency of hormone-induced mammary tumorigenesis To determine whether expression of a mutant p53 (R172H), which dimerizes with wild-type p53 and prevents its binding to DNA (Miller et al., 1993) , has an impact on hormone-induced mammary tumorigenesis, we bred the LH-overexpressing mice with WAPp53R172H transgenic mice. These mice rarely develop tumors in the absence of additional insults (Li et al., 1997) . Tumor formation was monitored in virgin LHoverexpressing and LH-overexpressing/p53R172H bitransgenic mice by weekly palpation. Statistical analysis revealed no change in tumor latency for bi-transgenic mice compared to LH-overexpressing mice despite strong expression of the p53 transgene in mammary glands of adult bi-transgenic animals ( Figure 5 ). In total, these data suggest that inactivation of p53 is not a rate-limiting step of hormone-induced mammary tumorigenesis in LH-overexpressing mice and other Figure 6 ). Most of these cells contained three or four centrosomes, but, in many cases, five or more centrosomes were present within a single cell. Such cells were not visually distinguishable from those containing a normal centrosome number (that is, nuclei were not pyknotic) indicating cells were not undergoing apoptosis. Most importantly, 12±2.1% (range ¼ 9.8-14% per gland) of epithelial cells from hyperplastic mammary glands of LH-overexpressing mice also had aberrant numbers of centrosomes. Thus, within the altered hormonal milieu of LH-overexpressing mice, a subset of MECs are incapable of appropriately regulating the centrosome cycle, resulting in centrosomal irregularities that precede tumor formation.
Discussion
Aneuploidy and genomic instability are common features of human tumors and are thought to contribute to the acquisition of malignant phenotypes (Cheng and Loeb, 1993) . The heterogeneous histopathology of mammary tumors of LH-overexpressing mice (Figure 1) suggests diverse initiating or promoting events caused by genomic instability, which is consistent with the high levels of aneuploidy observed (Figure 2 ). Furthermore, extensive intratumor chromosomal heterogeneity indicates that genomic instability is ongoing within tumors. This process probably induces a continuous state of genetic evolution within each tumor, generating complex genomic heterogeneity. The CGH analysis also suggests that there is an absence of a consistent selective pressure that would ultimately result in the conserved gain or loss of large chromosomal regions across the population of tumors.
A connection between altered p53 activity and aneuploidy has been revealed in a number of experimental systems (Donehower et al., 1992 (Donehower et al., , 1995 Fukasawa et al., 1997; Hundley et al., 1997) , including a report demonstrating that chronic hormone stimulation and loss of p53 cooperate to cause aneuploidy that precedes tumor development in transplanted MECs. Mammary glands with intact p53 exposed to the same paradigm failed to develop aneuploidy, suggesting that loss of p53 function is essential for hormone-induced chromosomal abnormalities (Goepfert et al., 2002; Pati et al., 2004) . Thus, we hypothesized that aneuploidy in mammary tumors of LH-overexpressing mice would be accompanied by loss of p53 function. However, the experiments reported herein indicate that p53 is intact in both hyperplastic mammary glands and in tumors. This apparent discrepancy may be because LH-overexpressing mice are chronically subjected to elevated ovarian hormones beginning at 5 weeks of age (Milliken et al., 2002) , while previous studies involved administration of reproductive steroids for only 3-5 weeks. These results suggest that, while hormone stimulation and loss of p53 can synergize to create genomic instability in MECs, extended hormonal stimulation via ovarian hyperstimulation can also induce aneuploidy through p53-independent mechanisms.
We expected increased mdm2 mRNA or protein levels in the hyperplastic glands and tumors of LH-overexpressing mice because estrogens can induce expression of the human homolog in breast cancer cell lines (Zell et al., 2002; Kinyamu and Archer, 2003) . Differences between these in vitro studies and the results reported herein may be due to the complex hormonal milieu of LH-overexpressing mice, which have elevated levels of multiple reproductive hormones (Mann et al., 1999; Milliken et al., 2002) . Specifically, while LH-overexpressing mice have elevated serum estradiol due to ovarian hyperstimulation, this process also leads to increases in progesterone, prolactin and corticosteroids, all of which can impact the proliferation and viability of MECs. Previous studies with these mice have shown that the ovaries are a central factor in their complex endocrinology (Kero et al., 2000; Milliken et al., 2002; Mohammad et al., 2003) . Identifying specific hormones that underlie changes in the centrosome cycle and aneuploidy will probably require the development of in vitro model systems due to the inability to manipulate a single hormone in any animal model without initiating a succession of endocrine responses.
In addition to chromosomal instability and aneuploidy, mammary tumors of LH-overexpressing mice exhibit centrosome amplification (Figure 6 ). Data showing centrosome amplification preceding tumorigenesis are consistent with the hypothesis that centrosomal abnormalities promote aneuploidy and tumorigenesis. Generation of aneuploid daughter cells from diploid HMEC precursors as a result of pseudo-bipolar or multipolar mitotic division was recently observed using time lapse image analysis (McDermott et al., 2006) . Despite the presence of wild-type p53, a subset of variant HMECs, termed vHMECs, also spontaneously accumulate centrosome abnormalities, abnormal mitotic metaphases and genomic abnormalities (for example, aneuploidy) if grown in culture for a sufficient period of time (Hammond et al., 1984; Romanov et al., 2001; McDermott et al., 2006) . The progressive increase in centrosome amplification and appearance of aneuploid cells that occurs in vHMECs parallels in vivo observations in mammary glands of LH-overexpressing mice, suggesting similar mechanisms may contribute to both. The presence of unaltered p53 in both systems clearly indicates MECs can bypass p53-mediated cell-cycle checkpoints. This is consistent with observations in human breast cancers-centrosome abnormalities demonstrate a linear correlation with aneuploidy and chromosomal instability, which occur independently of p53 mutation (Lingle et al., 2002) .
The source of aneuploid cells is not known in LHoverexpressing mice or in studies using HMECs. Given the heterogeneity observed in tumors from LH-overexpressing mice, it is possible these cells arise from progenitor or stem cells that generate aneuploid daughter cells through asymmetric cell division (Clarke et al., 2005) . These cells may embark upon failed differentiation patterns that ultimately give rise to distinct tumor histopathologies. Alternatively, gross changes in chromosomal configuration may generate tumors through distinct mechanisms that alter diverse regulators of cell fate.
It is unclear whether hormonally induced changes in the centrosome cycle in LH-overexpressing mice are due to direct effects in the mammary epithelium or the result of local environmental changes. Hormonally induced field cancerization (Slaughter et al., 1953; Braakhuis et al., 2003) may have caused changes in both the epithelial cells and surrounding stroma that initiate tumorigenic events, including centrosomal changes in the mammary epithelium. Notably, hyperplastic glands express estrogen and progesterone receptors while tumors lose this expression (Milliken et al., 2002 and data not shown). Thus, if ovarian hormones are directly responsible for changes in the centrosome cycle, the continued dysregulation in tumors must be due to either an irreversible earlier change or on-going changes in the cellular environment. Regardless of which cells are the direct targets of hormonal input, early changes in centrosomal content in hyperplastic epithelium, the high percentage of aneuploid cells in tumors, and extensive intratumoral variation in cellular chromosome number suggest that continuous aberrations of the centrosome cycle and gross chromosomal instability occur throughout the initiation and progression of tumors of LHoverexpressing mice. Understanding how mammogenic hormones regulate the centrosome cycle should lend considerable insight into the role of reproductive hormones in breast carcinogenesis.
Materials and methods

Animals
Mice were housed in microisolator plus units with a 12 h light/ dark cycle and were given food and water ad libitum. All mouse studies were approved by the Institutional Animal Care and Use Committee at Case Western Reserve University. Tissues for immunohistochemistry were fixed in 4% paraformaldehyde and embedded in paraffin. Irradiated mice were exposed to 5 Gy whole body irradiation administered using a 137 Cs irradiator and killed 2 or 6 h later. Virgin mice were used for all studies. WAP-p53R172H mice were generously provided by Jeff Rosen. Tumor latencies of LH and LH/p53R172H mice were plotted using Kaplan-Meier survival analysis and compared using the Cox-Mantel log-rank test.
Chromosome spread and centrosome analyses
The number 4 and 9 mammary glands were removed from mice, minced and suspended in medium 199 containing type III collagenase (400 U ml
À1
) and Dispase (1 mg ml À1 ). The suspension was gently agitated at 37 1C for 2 h. Cells were pelleted, washed and plated in medium 199 (Invitrogen, Carlsbad, CA, USA) containing 2% fetal bovine serum for 90 min to allow fibroblasts to attach.
To produce metaphase chromosome spreads, supernatants containing epithelial cells were collected, pelleted and suspended in Ham's F12 media (Invitrogen) containing insulin, hydrocortisone, transferrin, epidermal growth factor, Fungizone, gentamicin and 5% fetal bovine serum and Colcemid (1 mg ml À1 ) (Invitrogen) for 2 h. The cultures were pelleted, treated with 0.075 M KCl added dropwise, resuspended in methanol/acetic acid, and incubated at 4 1C overnight. Cells were pelleted and metaphase spreads were prepared, stained and mounted with Vectashield containing 4 0 ,6-diamidino-2-phenylindole (Vector Labs, Burlingame, CA, USA). A minimum of 50 metaphases were scored for each tumor. To circumvent the possibility that apparent hypoploidy was due to artifactual loss of chromosomes during the production of metaphase spreads, only cells with a minimum of 40 chromosomes were analysed.
For centrosome analysis, supernatant containing epithelial cells was collected, pelleted and suspended in Ham's F12 media (Invitrogen) containing 10 mg ml À1 insulin (Sigma), 500 ng ml À1 hydrocortisone (Sigma, St Louis, MO, USA), 0.01 mg ml À1 transferrin (Invitrogen), 5 ng ml À1 epidermal growth factor (Invitrogen), 1.5 mg ml À1 Fungizone (Invitrogen), 50 mg ml À1 gentamicin (Invitrogen) and 5% fetal bovine serum. Cells were cultured for 2 days, then fixed and permeabilized for immunocytochemistry. Cells were stained with monoclonal anti-g-tubulin (1:250; Sigma, catalog no. T6557) or E-cadherin (1:50; BD Biosciences, catalog no. 610181) overnight at 4 1C, goat anti-mouse AlexaFluor 594 1:500 (Invitrogen) on day two, and mounted with Vectashield containing 4 0 ,6-diamidino-2-phenylindole (Vector Labs). Centrosome numbers were counted in a minimum of 10 fields per tumor.
Measurement of apoptosis
Apoptosis was assessed using the ApopTag Red In Situ Apoptosis Detection Kit (Chemicon, Temecula, CA, USA, S7165) on 5-ı`m sections. Vectashield mounting media containing 4 0 ,6-diamidino-2-phenylindole were used as a counterstain. At least 1000 cells per animal were counted and differences were analysed using a Student's t-test.
Northern blot
Total RNA was isolated using TRIzol Reagent (Invitrogen). Total RNA (20 mg) was run on a 1.2 M formaldehyde 1% agarose gel and transferred onto Hybond-N þ Nytran membrane (GE Healthcare, Piscataway, NJ, USA). The doublestranded cDNA probe for p53 was generated by PCR using primers directed against p53 exons 6 and 7 (5 0 -GGAAATTTG TATCCCGAGTATCTG-3 0 and 5 0 -GTCTTCCAGTGTGAT GATGGTAA-3 0 (Yahagi et al., 2003) and radiolabeled with a-32P-labeled dCTP using the random priming DECAprime II kit (Ambion, Austin, TX, USA; catalog no. 1455).
CGH analysis
Genomic DNA was isolated from nine mammary tumors and their respective unaffected contralateral glands according to Agilent Technologies (Santa Clara, CA, USA) CGH protocol and hybridized to the CGH mouse 244 K array at the Agilent Technologies Center of Excellence. Data were analysed using CGH Analytics Software (Agilent Technologies). Common aberrations were detected by the context corrected common aberrations algorithm ADM-1 with a P-value threshold of 0.05 and overlap threshold of 0.9.
Additional detailed information regarding p53 sequence analysis, real-time RT-PCR and Western blotting are included in Supplementary Information.
